Xeris Biopharma Holdings, Inc. (XERS) Income Statement
XERS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsXERS revenue and net income
Where XERS's revenue goes
2025Each bar shows an amount and its share of revenue. XERS kept 0.2% of revenue as net income.
XERS profit margins
XERS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +43.7% | +38.3% | +154.7% | — |
| Gross profit | +43.4% | +39.6% | +192.2% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XERS quarterly EPS vs estimates
Xeris Biopharma beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $0.02).
XERS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $2.7M | $2.7M | $2.5M | $1.6M | $1.1M |
| Cost of revenue | $53.4M | $36.8M | $28.6M | $22.6M | $13.3M | $1.6M | $1.6M | $42,000 | $4,000 | $8,000 |
| Gross profit | $238.4M | $166.2M | $135.3M | $87.6M | $36.3M | $1.1M | $1.1M | $2.4M | $1.6M | $1.1M |
| Research & development | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $60.4M | $60.4M | $40.7M | $20.2M | $10.2M |
| Sales, general & admin | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M | $73.7M | $63.1M | $21.1M | $8.0M | $4.1M |
| Total operating expenses | $213.5M | $199.9M | $179.3M | $169.6M | $151.4M | $123.5M | $123.5M | $61.8M | $28.2M | $14.3M |
| Operating income | $24.9M | −$33.6M | −$44.0M | −$81.9M | −$115.2M | −$122.4M | −$122.4M | −$59.3M | −$26.6M | −$13.2M |
| Interest income | $4.7M | $5.3M | $4.8M | $2.6M | $313,000 | $3.0M | $2.8M | $1.6M | $124,000 | $5,000 |
| Interest expense | $29.1M | $33.2M | $26.6M | $14.1M | $7.2M | $7.2M | $7.2M | $2.5M | $2,000 | $2,000 |
| Income before taxes | $554,000 | −$57.1M | −$63.5M | −$96.1M | −$122.7M | −$126.0M | −$126.0M | −$60.1M | −$26.6M | −$13.2M |
| Income taxes | — | −$2.3M | −$1.2M | −$1.4M | −$110,000 | −$458,000 | −$458,000 | $1.8M | $1,000 | −$3,000 |
| Net income | $554,000 | −$54.8M | −$62.3M | −$94.7M | −$122.7M | −$125.6M | −$125.6M | −$60.1M | −$26.6M | −$13.2M |
| EBITDA | $12.7M | −$14.0M | −$23.7M | −$69.3M | −$113.7M | −$117.8M | −$119.6M | −$57.2M | −$26.4M | −$13.1M |
| EPS (diluted) | −$0.01 | −$0.33 | −$0.45 | −$0.70 | −$1.52 | −$2.28 | −$4.80 | −$9.45 | −$9.67 | −$2.29 |
| Gross margin | 81.7% | 81.9% | 82.5% | 79.5% | 73.1% | 41.1% | 41.1% | 98.3% | 99.7% | 99.3% |
| Operating margin | 8.5% | −16.6% | −26.8% | −74.3% | −232.2% | −4,496.0% | −4,496.0% | −2,407.5% | −1,711.4% | −1,230.8% |
| Net margin | 0.2% | −27.0% | −38.0% | −85.9% | −247.5% | −4,613.5% | −4,613.5% | −2,437.3% | −1,706.6% | −1,228.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.1M | $83.1M | $85.8M | $74.4M | $71.5M | $60.1M | $60.1M | $54.3M | $48.1M | $40.6M | $44.4M | $48.3M |
| Cost of revenue | $12.5M | $13.3M | $19.1M | $11.0M | $14.6M | $8.7M | $9.5M | $13.6M | $10.5M | $6.0M | $10.3M | $8.2M |
| Gross profit | $79.6M | $69.8M | $66.7M | $63.4M | $56.9M | $51.4M | $50.6M | $40.7M | $37.6M | $34.7M | $34.1M | $40.1M |
| Research & development | $10.7M | $8.8M | $7.9M | $7.5M | $8.1M | $7.8M | $6.1M | $5.9M | $5.8M | $7.8M | $6.4M | $5.0M |
| Sales, general & admin | $61.0M | $53.1M | $47.5M | $46.5M | $44.4M | $44.0M | $40.1M | $45.0M | $40.0M | $38.4M | $37.6M | $37.3M |
| Total operating expenses | $74.4M | $61.9M | $50.0M | $56.7M | $52.4M | $54.5M | $48.9M | $53.6M | $45.8M | $48.9M | $44.0M | $45.0M |
| Operating income | $5.2M | $7.9M | $16.8M | $6.7M | $4.5M | −$3.1M | $1.7M | −$12.9M | −$8.2M | −$14.2M | −$9.8M | −$4.9M |
| Interest income | $1.5M | $1.2M | $1.5M | $1.2M | $948,000 | $1.2M | $910,000 | $1.2M | $1.3M | $1.9M | $1.1M | $1.1M |
| Interest expense | $6.9M | $6.9M | $7.2M | $7.3M | $7.4M | $7.3M | $7.7M | $7.8M | $8.0M | $7.0M | $7.0M | $6.8M |
| Income before taxes | −$31.1M | $2.2M | $11.1M | $621,000 | −$1.9M | −$9.2M | −$5.1M | −$19.1M | −$14.3M | −$18.7M | −$13.6M | −$12.5M |
| Income taxes | — | — | — | — | — | — | — | −$3.3M | $749,000 | $307,000 | −$236,000 | −$338,000 |
| Net income | −$31.1M | $2.2M | $11.1M | $621,000 | −$1.9M | −$9.2M | −$5.1M | −$15.7M | −$15.0M | −$19.0M | −$13.4M | −$12.2M |
| EBITDA | −$20.9M | $12.3M | $14.1M | $11.1M | $8.6M | $1.2M | $5.7M | −$8.2M | −$3.1M | −$8.4M | −$3.3M | −$2.3M |
| EPS (diluted) | −$0.01 | $0.01 | $0.06 | $0.00 | −$0.01 | −$0.06 | −$0.03 | −$0.06 | −$0.10 | −$0.14 | −$0.10 | −$0.09 |
| Gross margin | 86.4% | 84.0% | 77.8% | 85.2% | 79.6% | 85.5% | 84.2% | 75.0% | 78.2% | 85.3% | 76.8% | 83.0% |
| Operating margin | 5.6% | 9.5% | 19.5% | 9.0% | 6.3% | −5.1% | 2.8% | −23.8% | −17.0% | −35.1% | −22.2% | −10.2% |
| Net margin | −33.8% | 2.7% | 12.9% | 0.8% | −2.7% | −15.3% | −8.5% | −29.0% | −31.2% | −46.7% | −30.2% | −25.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XERS's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XERS financial results
In fiscal year 2025 (ended December 31, 2025), Xeris Biopharma reported revenue of $291.8 million, up 43.7% from the year before. It had net income of $0.6 million, a net profit margin of 0.2%. Diluted earnings per share came to −$0.01. Over five years revenue grew at an average rate of 154.7% a year.
See the XERS stock overview for the latest quote and news, or the XERS chart for price history and technical indicators.
XERS income statement FAQ
What is Xeris Biopharma's annual revenue?
Xeris Biopharma reported total revenue of $291.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 43.7% from $203.1 million the previous year.
Is Xeris Biopharma profitable?
Yes. Xeris Biopharma reported net income of $0.6 million in fiscal 2025, a net profit margin of 0.2%; its operating margin was 8.5%.
What is Xeris Biopharma's gross margin?
Xeris Biopharma's gross margin was 81.7% in fiscal 2025: for every $100 of revenue, Xeris Biopharma kept $82 after the direct cost of its products and services.
How much does Xeris Biopharma spend on research and development?
Xeris Biopharma spent $31.2 million on research and development in fiscal 2025, 10.7% of revenue.
How fast is Xeris Biopharma growing?
Revenue grew 154.7% a year on average over the last five fiscal years, from $2.7 million to $291.8 million.
What are Xeris Biopharma's earnings per share?
Xeris Biopharma earned $-0.01 per diluted share in fiscal 2025, compared with $-0.33 a year earlier.
When will Xeris Biopharma report its next earnings?
Xeris Biopharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Xeris Biopharma's fiscal year end?
Xeris Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.